Table 3.
Treatment‐emergent adverse events (TEAEs) in cycle 1
| TEAE category, n (%) | 2U/kg AboBoNT‐A (n=70) | 8U/kg AboBoNT‐A (n=70) | 16U/kg AboBoNT‐A (n=70) |
|---|---|---|---|
| Any TEAE | 45 (64.3) | 40 (57.1) | 33 (47.1) |
| Intensity of TEAE | |||
| Mild | 38 (54.3) | 34 (48.6) | 25 (35.7) |
| Moderate | 14 (20.0) | 13 (18.6) | 15 (21.4) |
| Severe | 2 (2.9) | 4 (5.7) | 1 (1.4) |
| Any related TEAE | 2 (2.9) | 6 (8.6) | 6 (8.6) |
| Any serious TEAE | 3 (4.3) | 2 (2.9) | 2 (2.9) |
| Any TEAE leading to withdrawal | 2 (2.9) | 0 | 0 |
| Any TEAE leading to death | 0 | 0 | 0 |
AboBoNT‐A, abobotulinumtoxinA.